TGRX-678 US Phase I for Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia Clinical Trial

Official title:

A Single-arm, Open-label, Dose Escalation + Cohort Expansion Phase 1 Trial on Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TGRX-678 in Subjects With Refractory or Advanced Chronic Myelogenous Leukemia

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT06088888
• Other study ID #: TGRX-678-07-101
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: March 15, 2024
• Est. completion date: June 30, 2027

Study information

• Verified date: February 2024
• Source: Shenzhen TargetRx, Inc.
• Contact: Xinyi Zhu
• Phone: 86-13061651609
• Email: xinyi.zhu[@]tjrbiosciences.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this single-arm, open-label, dose escalation + cohort expansion study is to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of TGRX-678 in Chronic Myelogenous Leukemia patients who had failure with or are intolerant to TKI treatments.

Description:

This is the first trial with TGRX-678 conducted to US patients which aims to evaluate the safety profile and preliminary efficacy profile in advanced or refractory CML patients with previous failure or intolerance to TKI treatments. The primary purpose of this study is to evaluate the safety profile of TGRX-678, including determination of the recommended dose for expansion (RDE) and other safety measures of the investigational drug, such as adverse events and abnormal clinical outcomes. Preliminary efficacy profile of TGRX-678 is evaluated based on the changes in peripheral blood cells and disease-associated cytogenetic and molecular markers. Recommended Phase II dose (RP2D) will be determined at end of the study considering safety, tolerability, pharmacokinetic and efficacy data.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 90
• Est. completion date: June 30, 2027
• Est. primary completion date: March 30, 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Willing to participate in the study with informed consent;
• At least 18 years of age at the time of screening;
• Any sex;
• Diagnosis of CML-CPduring the screening period;
• Intolerant or resistant to TKI treatments;
• Eastern Cooperative Oncology Group (ECOG) performance status = 2;
• Adequate Absolute neutrophil count (ANC), hemoglobin and platelets levels;
• Adequate renal and liver function;
• Normal corrected QT (QTcF) interval as indicated by electrocardiogram (ECG) screening results;
• Negative blood pregnancy test results for female patients of childbearing potential.
• Willing to take highly effective contraceptive measures throughout the trial and for 6 months after last dose of investigational drug for female subjects of child-bearing potential or male subject with female partner of child-bearing potential.

Exclusion Criteria:

• Exposure to other antineoplastic therapies prior to study enrollment;
• Exposure to other investigational agent(s) within 14 days of initiating TGRX-678 therapy;
• Ongoing toxicity from prior therapy greater than grade 1 by CTCAE v. 3 (except alopecia);
• Hematopoietic cell transplantation < 60 days prior to the first dose;
• Evidence of graft versus host disease (GVHD), whether or not requiring immunosuppressive therapy;
• Concomitant immunosuppressive therapy (other than short-term corticosteroid treatment);
• Exposure to drugs related to torsade de pointes;
• Cytological or pathological diagnosis of active central nervous system disorder;
• Significant or uncontrolled cardiovascular diseases as defined in the full clinical protocol;
• Having long QT syndrome, or with family history of idiopathic sudden death or congenital long QT syndrome;
• Uncontrolled hypertension;
• Receipt of Traditional Chinese medication or herbal preparations indicated for anti-cancer purposes within 2 weeks prior to the first dose;
• Severe hemorrhagic disorders unrelated to CML;
• History of pancreatitis;
• History of excessive alcohol use;
• History of elevation in amylase or lipase within 1 year;
• Have Grade 2 or worse interstitial lung disease or interstitial pneumonitis within 4 weeks prior to Screening;
• Uncontrolled hypertriglyceridemia;
• Malabsorption syndrome or other illness that could affect oral absorption.
• Diagnosis of another primary malignancy in the past 3 years;
• Reception of major surgery within 14 days prior to the first dose;
• Active infections that require systemic treatment or other severe infections within 14 days prior to enrollment;
• Known human immunodeficiency virus (HIV) positive; acute or chronic liver disease (including chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections);
• Have received or will receive a COVID-19 vaccine within 14 days of study enrollment;
• Have a positive reverse transcriptase polymerase chain reaction (RT-PCR) test result for SARS-CoV-2 within 2 weeks prior to Screening;
• Pregnant or breastfeeding female;
• Female patient of child-bearing potential or male patient who have female partners of child-bearing potential that is unable or unwilling to take highly effective contraceptive measures during the trial and for 6 months after last dose of investigational drug;
• Significant organ dysfunction that could compromise the patient's safety or the evaluation of the drug's safety in the opinion of the investigator or the medical monitor;
• Any condition makes participation in this trial inappropriate in the opinion of the investigator or medical monitor;

Related Conditions & MeSH terms

• Chronic Myelogenous Leukemia
• Leukemia
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive
• Leukemia, Myeloid

Intervention

Drug:
• TGRX-678
Participants are given TGRX-678 tablets orally, once daily, at one of the dose levels as pre-determined for the dose escalation sequence or expansion cohorts.

Locations

Country	Name	City	State
United States	The University of Texas MD Anderson Cancer Center	Houston	Texas

Sponsors (2)

Lead Sponsor	Collaborator
Shenzhen TargetRx, Inc.	M.D. Anderson Cancer Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recommended dose for expansion (RDE)	To determine the RDE of TGRX-678 in CML patients to be applied in Cohort Expansion part of the study	Time Frame: At end of Dose Escalation part of study, an average of 1 year
Primary	Safety profile (DLT)	to record and analyse subjects with dose-limiting toxicities (DLTs)	Time Frame: DLT: collect during Cycle 1 (28 days)
Primary	Safety profile (AEs/SAEs)	to record and analyse subjects with adverse events (AEs) and serious adverse events (SAEs)	AE and SAE: through completion of the study, an average of 2 years
Primary	Recommended phase II dose (RP2D)	To determine the RP2D of TGRX-678 in CML patients for Phase II	At completion of the study, an average of 2 years
Secondary	Hematologic Response	To record and analyse the hematologic response of subjects. Subjects will be determined whether complete hematologic response (CHR) or no evidence of leukemia (NEL) is reached.	at screening period, weekly in Cycle 1, bi-weekly in Cycle 2 and monthly starting from Cycle 3 (each cycle is 28 days), an average of 1.5 years
Secondary	Cytogenetic Response	To record and analyse the cytogenetic response of subjects subjects will be determined whether partial or complete cytogenetic response (Ph+ < 35%) is reached.	at screening period, end of every 3 Cycles (each cycle is 28 days), an average of 1.5 years
Secondary	Molecular Response	To record and analyse the molecular response of subjects Subjects will be determined whether major molecular response (BCR-ABL1 (IS) no more than 0.1%) is reached.	at screening period, end of every 3 Cycles (each cycle is 28 days), an average of 1.5 years
Secondary	Plasma Cmax	Cmax of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Plasma Tmax	Tmax of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Plasma T1/2	T1/2 of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Plasma AUClast	AUClast of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Plasma AUCinf	AUCinf of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Plasma Cmin	Cmin of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Plasma AUCss	AUCss of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Plasma Cmax,ss	steady state Cmax of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Plasma Tmax,ss	steady state Tmax of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	CL (Clearance)	Clearance of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)
Secondary	Vd (Volume of distribution)	Volume of distribution of TGRX-678 as measured in plasma	Day 1, 7, 21, 28 of Cycle 1, and Day 28 of Cycle 2, 3 and 5 (each cycle is 28 days)